No reliable published quarterly consensus makes a precise beat-or-miss call unavailable. The filing provides no revenue, adjusted-loss, or cash-burn guidance, and the available market context does not establish a dependable Q2 estimate. The cleanest anchor is therefore the company’s prior-year period and the expectations already created by its June IPO and previously disclosed development plans.
| Metric | Q2 2026 | Q2 2025 | Comparison / expectation |
|---|---|---|---|
| R&D expense | $56.4 million | $35.8 million | Up $20.5 million as trials advance (Financial Results) |
| G&A expense | $18.9 million | $21.3 million | Down $2.4 million, partly due to a prior-year one-time bonus (Financial Results) |
| Fair-value change in contingent milestone liabilities | $43.5 million | — | Large non-cash charge (Statement of Operations) |
| Net loss | $116.2 million | $57.4 million | Loss more than doubled, mainly from higher R&D and the milestone revaluation (Financial Results; Statement of Operations) |
| Net loss per share | $4.61 | $4.64 | Slightly improved because weighted-average shares rose to 25.2 million from 12.4 million (Statement of Operations) |
| Cash, cash equivalents and investments | $660.7 million | — | Up from $335.5 million at December 31, 2025, following the IPO (Balance Sheet) |
| IPO gross proceeds | $460 million | — | Recently completed financing, before offering costs (Additional Highlights) |
The operational update is constructive but largely execution, not new clinical evidence. Kardigan completed enrollment of the first danicamtiv KINSHIP-DCM cohort, began enrollment in the Phase 3 portion, randomized the first patient in KARDINAL-ASH, and continued KATALYST-AV enrollment. The company still expects the main Phase 2b or Phase 2 readouts in the first half of 2027, so the filing does not reduce the central clinical-risk timetable (Danicamtiv; Ataciguat; Tonlamarsen).
Funding risk is meaningfully lower after the IPO, but spending is accelerating. Cash of $660.7 million supports multiple clinical readouts and planned Phase 3 starts, which is the strongest tangible change in the quarter (Balance Sheet; Additional Highlights). At the same time, R&D spending rose 57% year over year to $56.4 million, showing that the stronger balance sheet is being converted into a faster and more expensive development program (Financial Results).
The headline net loss overstates the quarter’s cash operating deterioration, but underlying burn still increased. The $43.5 million fair-value increase in contingent milestone liabilities is a non-cash accounting charge (Statement of Operations). Excluding that item, operating expenses were approximately $75.2 million versus $57.1 million a year earlier—still a substantial increase, consistent with three programs moving deeper into clinical development.
Net read: better financed and advancing on schedule, but not a clear positive surprise. The filing improves visibility into execution and removes near-term financing pressure, while offering no efficacy data, accelerated milestone timing, or raised outlook. Against expectations already shaped by the IPO and prior trial plans, this is best characterized as a mixed update rather than a substantiated earnings beat.
Read the original 8-K on SEC EDGAR ↗